Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,000 shares of the company’s stock after selling 1,500 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Neurocrine Biosciences were worth $5,929,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System bought a new position in shares of Neurocrine Biosciences in the 4th quarter worth about $3,637,000. Cerity Partners LLC bought a new position in shares of Neurocrine Biosciences in the 4th quarter worth about $575,000. Toth Financial Advisory Corp bought a new position in shares of Neurocrine Biosciences in the 4th quarter worth about $539,000. Allspring Global Investments Holdings LLC lifted its position in shares of Neurocrine Biosciences by 81.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 410,103 shares of the company’s stock worth $54,035,000 after buying an additional 184,660 shares during the last quarter. Finally, International Assets Investment Management LLC lifted its position in shares of Neurocrine Biosciences by 7,880.3% in the 4th quarter. International Assets Investment Management LLC now owns 5,666 shares of the company’s stock worth $747,000 after buying an additional 5,595 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 5,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $145.06, for a total value of $725,300.00. Following the completion of the sale, the insider now directly owns 7,507 shares in the company, valued at $1,088,965.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Ingrid Delaet sold 5,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $145.06, for a total value of $725,300.00. Following the transaction, the insider now owns 7,507 shares of the company’s stock, valued at $1,088,965.42. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Eric Benevich sold 75,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $139.38, for a total transaction of $10,453,500.00. Following the completion of the transaction, the insider now directly owns 40,778 shares in the company, valued at approximately $5,683,637.64. The disclosure for this sale can be found here. Insiders sold 177,176 shares of company stock worth $24,562,081 over the last ninety days. 4.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

NBIX has been the topic of several recent research reports. Barclays lifted their price objective on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Tuesday, January 23rd. Citigroup cut their price objective on shares of Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating on the stock in a research report on Thursday, February 8th. StockNews.com raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, April 10th. Finally, Mizuho raised their target price on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday, February 8th. Six analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $139.25.

Neurocrine Biosciences Stock Performance

NBIX stock opened at $131.74 on Tuesday. The stock has a market cap of $13.11 billion, a P/E ratio of 54.44 and a beta of 0.25. The firm has a 50 day simple moving average of $136.45 and a 200 day simple moving average of $126.62. Neurocrine Biosciences, Inc. has a 52 week low of $89.04 and a 52 week high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.13 by $0.31. The business had revenue of $515.20 million during the quarter, compared to analysts’ expectations of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The firm’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same period last year, the company posted $0.88 earnings per share. Sell-side analysts predict that Neurocrine Biosciences, Inc. will post 4.84 EPS for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.